Menu Search
Equities

EvoNext Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ADF0:STU

EvoNext Holdings Ltd

Actions
  • Price (EUR)0.84
  • Today's Change0.002 / 0.24%
  • Shares traded20.00
  • 1 Year change--
  • Beta0.3742
Data delayed at least 15 minutes, as of Feb 09 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

  • Revenue in CHF (TTM)0.00
  • Net income in CHF-850.90k
  • Incorporated1997
  • Employees0.00
  • Location
    EvoNext Holdings LtdDuggingerstrasse 23REINACH 4153SwitzerlandCHE
  • Phone+41 614852000
  • Fax+41 614852001
  • Websitehttps://evonextholdings.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EVE:SWX since
announced		Transaction
value
Gzo AG Spital WetzikonDeal completed27 May 202527 May 2025Deal completed-17.76%--
Data delayed at least 15 minutes, as of Feb 10 2026 13:23 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.